Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a price target of $7.
October 01, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Mereo BioPharma Group and maintained a $7 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a maintained price target of $7 by Cantor Fitzgerald suggests a positive outlook for Mereo BioPharma Group. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100